An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06589596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), and in combination with standard of care therapy in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.
Study identification
- NCT ID
- NCT06589596
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 525 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 9, 2025
- Primary completion
- Sep 29, 2027
- Completion
- Sep 29, 2027
- Last update posted
- Jul 21, 2026
2025 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Usc Norris Comprehensive Cancer Center (Nccc) | Los Angeles | California | 90089-1019 | Recruiting |
| Adventhealth | Celebration | Florida | 34747-4606 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215-5418 | Recruiting |
| Washington University School of Medicine | St Louis | Missouri | 63110-1010 | Recruiting |
| Nyu Langone Health | New York | New York | 10016-2708 | Recruiting |
| Columbia University Medical Center | New York | New York | 10032 | Recruiting |
| Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107-4307 | Recruiting |
| Tennessee Oncology, Pllc Nashville | Nashville | Tennessee | 37203 | Recruiting |
| The University of Texas Md Anderson Cancer Center | Houston | Texas | 77030-4009 | Recruiting |
| Next Dallas | Irving | Texas | 75039-2743 | Recruiting |
| Next Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06589596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06589596 live on ClinicalTrials.gov.